Showing results (1-10 of 112) with videos related to
Sort By:
Pageof 12
Therapeutic Innovation & Regulatory Science|September 27, 2024
Paediatric Drug Development in Japan: Current Status and Future ChallengesRieko Inagaki, Mamoru NarukawaThe Annals of Pharmacotherapy|February 10, 2018
Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard RatioMasayuki Kaneko, Mamoru NarukawaClinical Drug Investigation|March 27, 2013
Investigation of influencing factors on higher placebo response in East Asian versus Western clinical trials for partial epilepsy: a meta-analysisYosuke Tachibana, Mamoru NarukawaJournal of Clinical Pharmacology|May 22, 2025
Comparison of Population Pharmacokinetics-Related Information in Drug Labeling Between Japan, the United States, and the European UnionKei Fukuhara, Mamoru NarukawaPharmacoepidemiology and Drug Safety|August 13, 2025
Comparison of Prescribing Information for Elderly Patients on Drug Labels in Japan, the United States, and EuropeMakoto Onohara, Mamoru NarukawaInternational Journal of Clinical Pharmacology and Therapeutics|July 19, 2014
Investigation of the relationship between a starting dose in first-in-human studies and no observed adverse effect level in nonclinical studiesAkihide Sato, Mamoru NarukawaClinical Drug Investigation|March 20, 2019
Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes MellitusMasayuki Kaneko, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|February 6, 2022
Estimation of the Under-Reporting of Suspected Serious Adverse Drug Reactions in Japan Using An Interrupted Time Series AnalysisSatoru Ito, Mamoru NarukawaClinical and Translational Science|February 19, 2025
Bridging Gaps in Oncology: Comparative Analysis of Development and Approval Pathways for Anticancer Drugs and Companion Diagnostic in the United States and JapanKaku Saito, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|April 23, 2024
Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in OncologyAkio Maki, Mamoru NarukawaPageof 12